Evidence map›Paper›PMID 41155905›Full record

ArticlePharmaceutics2025

Rational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell Carcinoma.

Valentin Mieville, Jakub Gubala, Mathis Fiault, Marie Ota, Seungsu Han, Muriel Urwyler, Daniel Benamran, Jean-Christophe Tille, Massimo Valerio, Patrycja Nowak-Sliwinska

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valentin MievilleSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.ORCID 0009-0003-4626-0377
Jakub GubalaSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-1622-854X
Mathis FiaultSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.
Marie OtaSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.
Seungsu HanSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.
Muriel UrwylerSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.
Daniel BenamranDivision of Urology, Geneva University Hospitals, 1211 Geneva, Switzerland.
Jean-Christophe TilleDivision of Pathology, Geneva University Hospitals, 1205 Geneva, Switzerland.ORCID 0000-0002-2255-5918
Massimo ValerioDivision of Urology, Geneva University Hospitals, 1211 Geneva, Switzerland.ORCID 0000-0002-1059-2340
Patrycja Nowak-SliwinskaSchool of Pharmaceutical Sciences, Faculty of Science, University of Geneva, 1211 Geneva, Switzerland.ORCID 0000-0002-8299-0444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ccRCCchRCCdrug combinationshypoxiapatient-derived organoidsRCCsafetyscreeningspheroids

Identifiers

PMID41155905
PMCPMC12567191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.